Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics, Inc. (LXEO) reported that its Chief Financial Officer, Louis Edward Tamayo, sold 4,117 shares of common stock on 2026-08-18 at a weighted average price of $4.91 per share. According to the company’s disclosure, this sale represents shares sold to cover tax obligations arising from the release of restricted stock units. After this transaction, Tamayo directly holds 92,907 shares of Lexeo common stock, including 78,415 Restricted Stock Units.
Lexeo Therapeutics, Inc. (LXEO) reported that Chief Executive Officer and director Richard Nolan Townsend sold 3,345 shares of Common Stock on 2026-08-18. The sale, at a weighted average price of $4.9512 per share (individual trades ranged from $4.83 to $5.01), was to cover tax obligations on the release of restricted stock units (RSUs). Following this transaction, he directly holds 374,472 shares of Lexeo common stock, which includes 242,911 RSUs.
Lexeo Therapeutics, Inc. (LXEO) reported that Chief Operating Officer Jose Manuel Otero sold 1,304 shares of common stock on August 18, 2026 at a weighted average price of $4.9571 per share. The sale was made to cover tax obligations arising from the release of restricted stock units. Following this transaction, Otero directly holds 136,178 shares of Lexeo common stock, including 97,026 Restricted Stock Units.
Lexeo Therapeutics, Inc. (LXEO) is the issuer for a planned sale of common stock under Rule 144 by Richard N. Townsend. A brokerage account at Fidelity Brokerage Services LLC indicates 3,345 shares of common stock are intended to be sold, with the securities becoming available through restricted stock vesting dated 08/17/2026. In the prior three months, Townsend reported sales of 3,342 shares on 05/18/2026 and 25,947 shares on 07/01/2026. The notice states that part of the sale proceeds will cover a tax obligation arising from the settlement of a vested equity award distribution.
Lexeo Therapeutics, Inc. (LXEO) has a stockholder, Jose Manuel Otero, filing a notice of proposed sale of company stock under Rule 144. The notice covers an intended sale of 1,304 shares of common stock through Fidelity Brokerage Services LLC on or after 08/18/2026.
The shares relate to restricted stock vesting on 08/17/2026 as part of compensation from the issuer. In the past three months, Otero has reported selling 1,302 shares on 05/18/2026 for $6,606.35 and 4,666 shares on 07/01/2026 for $20,919.08. A remark states that the sale includes shares needed to cover a tax obligation arising from settlement of a vested equity award.
Lexeo Therapeutics, Inc. (LXEO) disclosed that Louis E. Tamayo intends to sell common stock under Rule 144 through Fidelity Brokerage Services LLC. The planned sale covers 4,117 shares of common stock on NASDAQ, arising from restricted stock vesting, with part of the sale used to satisfy a tax obligation from a vested equity award. In the prior three months, Tamayo sold 4,641 shares of common stock for total proceeds of 20,814.89.
Lexeo Therapeutics, Inc. has been reported as held by funds affiliated with OrbiMed. OrbiMed Advisors LLC reports beneficial ownership of 3,203,050 shares of common stock, representing 4.1% of the class, with shared voting and dispositive power over these shares and no sole power. OrbiMed Capital LLC reports beneficial ownership of 744,800 shares, representing 1.0% of the class, with sole voting and dispositive power over these shares. In the aggregate, the reporting persons state they hold 5.0% of Lexeo’s common stock on behalf of other persons entitled to dividends or sale proceeds. Investment and voting power is exercised through a management committee of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the reported shares.
Lexeo Therapeutics, Inc. has a Schedule 13G/A (Amendment No. 3) reporting beneficial ownership of its common stock by Paradigm BioCapital-related entities and Senai Asefaw, M.D. Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC and Senai Asefaw each report beneficial ownership of 4,175,382 shares of common stock, representing 5.3% of the class, with sole voting and dispositive power over these shares. Paradigm BioCapital International Fund Ltd. reports beneficial ownership of 3,662,102 shares, representing 4.7% of the class, also with sole voting and dispositive power. Percentages are based on 78,521,634 shares of common stock outstanding as of May 7, 2026.
Investment entities affiliated with Balyasny Asset Management report beneficial ownership of 7,844,311 shares of Lexeo Therapeutics, Inc. common stock, representing 9.99% of the class based on 78,521,634 shares outstanding as of May 7, 2026. The position is held through Atlas Diversified Master Fund, Ltd., which directly owns 1,277,597 shares, and Atlas Private Holdings (Cayman) Ltd., which directly owns 6,566,714 shares, including 5,431,569 shares issuable upon exercise of 5,586,529 warrants subject to a 9.99% Beneficial Ownership Limitation. Each reporting person is listed as having sole voting and dispositive power over the 7,844,311 shares, with no shared power.
Lexeo Therapeutics, Inc. has a significant shareholder position reported by Affinity Asset Advisors, LLC and Michael Cho in an amended Schedule 13G. As of June 30, 2026, they beneficially own 6,674,913 shares of Lexeo common stock, including 867,302 shares issuable upon exercise of warrants.
This position represents approximately 8.4% of Lexeo’s common stock, based on 78,521,634 shares outstanding as of May 7, 2026, plus the warrant shares. The reporting persons have sole voting and dispositive power over all 6,674,913 shares and no shared voting or dispositive authority.